Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
|ClinicalTrials.gov Identifier: NCT01537861|
Recruitment Status : Terminated (Unexpected toxicity (2 early deaths))
First Posted : February 23, 2012
Last Update Posted : January 26, 2015
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Filgrastim Drug: Bortezomib Drug: Carfilzomib Drug: Dexamethasone Drug: Cyclophosphamide Drug: Thalidomide Drug: Lenalidomide Drug: Pomalidomide||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||December 2014|
U.S. FDA Resources
Experimental: Arm 1
Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.
Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.
Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.
PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen.
Other Names:Drug: Bortezomib
Other Name: Velcade®Drug: Carfilzomib
Other Name: Kyprolis®Drug: Dexamethasone Drug: Cyclophosphamide
Other Name: CytoxanDrug: Thalidomide
Other Name: ThalomidDrug: Lenalidomide
Other Name: RevlimidDrug: Pomalidomide
Other Name: Pomalyst
- Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma. [ Time Frame: Up to 30 days after last treatment ]Number and grade of adverse events based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
- Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow [ Time Frame: 14 days after last drug treatment ]
- Response rate as defined by the International Myeloma Working Group (IMWG) criteria [ Time Frame: 14 days after last drug treatment ]
- Overall survival duration of patients treated on study [ Time Frame: 1 year ]Defined as the date of first dose of study drug to the date of death from any cause.
- Progression-free survival of patients treated on study [ Time Frame: 1 year ]Defined as the interval from the date of first treatment to date of first documentation of disease progression.
- Duration of response of patients treated on study [ Time Frame: 1 year ]Defined as the interval from the date of first documentation of response to the first documentation of disease progression.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01537861
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63110|
|Principal Investigator:||Ravi Vij, M.D.||Washington University School of Medicine|